Research Updates of Plasmid-Mediated Aminoglycoside Resistance 16S rRNA Methyltransferase

Weiwei Yang¹,² and Fupin Hu¹,²,*

¹ Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; 21211220038@m.fudan.edu.cn
² Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai 200040, China
* Correspondence: hufupin@fudan.edu.cn

Abstract: With the wide spread of multidrug-resistant bacteria, a variety of aminoglycosides have been used in clinical practice as one of the effective options for antimicrobial combinations. However, in recent years, the emergence of high-level resistance against pan-aminoglycosides has worsened the status of antimicrobial resistance, so the production of 16S rRNA methyltransferase (16S-RMTase) should not be ignored as one of the most important resistance mechanisms. What is more, on account of transferable plasmids, the horizontal transfer of resistance genes between pathogens becomes easier and more widespread, which brings challenges to the treatment of infectious diseases and infection control of drug-resistant bacteria. In this review, we will make a presentation on the prevalence and genetic environment of 16S-RMTase encoding genes that lead to high-level resistance to aminoglycosides.

Keywords: aminoglycosides; antimicrobial resistance; 16S rRNA methyltransferases

1. Introduction

Aminoglycoside antibiotics were discovered and isolated from soil Actinobacteria in the 1940s, and streptomycin was the first aminoglycoside antibiotic used in the clinical treatment of tuberculosis and Gram-negative bacteria infection [1]. The mechanism of aminoglycosides is to bind the A site of 16S rRNA, which consists of the 30S ribosomal subunit, leading to the inhibition of protein synthesis and bacteria death [2]. Therefore, aminoglycosides have a broad spectrum of antimicrobial activity against both Gram-positive and Gram-negative bacteria and are often used in combination with β-lactam antibiotics, especially the third-generation cephalosporins [3].

Since the 1980s, due to the side effects of ototoxicity and nephrotoxicity, aminoglycosides have been used less and less in clinics and gradually replaced by β-lactams and quinolones, which are less toxic and have a wider antimicrobial spectrum [4]. However, with the increase of β-lactams and quinolone antimicrobial resistance and the prevalence of multidrug-resistant bacteria, the retained potency of aminoglycoside antibiotics has renewed interest in their use in clinical practice [5]. Additionally, aminoglycosides can be used as one of the effective antimicrobial combinations for the treatment of life-threatening infections caused by multidrug-resistant bacteria. Because aminoglycosides can be used in combination with other antibiotics, the toxicity can be decreased by adjusting the dosage [6]. However, in recent years, reports about high-level resistance to aminoglycosides have increased and spread widely around the world. In this review, we will make a presentation on the prevalence and genetic environment of 16S-RMTases, which lead to high-level resistance to pan-aminoglycosides.

2. Antimicrobial Resistance Mechanism of Aminoglycosides

According to the difference in chemical structures, aminoglycosides can be divided into 4,5-disubstituted 2-deoxystreptamine (DOS), such as neomycin and paromomycin;
4,6-disubstituted 2-DOS, such as gentamicin, amikacin, kanamycin, arbekacin, and tobramycin; monosubstituted DOS, such as apramycin; and no DOS ring, such as streptomycin [1,4]. The mechanisms of aminoglycosides resistance include: (1) modification or inactivation of aminoglycosides modifying enzymes; (2) increased expression of efflux pump; (3) decreased drug permeability; and (4) modification of the drug target, such as generating 16S-RMTases that interfere with binding of the aminoglycosides [7]. Numerous studies have shown that aminoglycosides modifying enzymes and 16S-RMTases can lead to high-level resistance to aminoglycosides in bacteria. Aminoglycosides modifying enzymes are the most common mechanism of aminoglycosides resistance in bacteria, consisting of aminoglycoside acetyltransferases, aminoglycoside phosphotransferases, and aminoglycoside nucleotidylintransferases [5]. The above three aminoglycoside modification enzymes can catalyze the modification of different OH and NH$_2$ groups of 2-DOS molecules. Because the encoding genes of aminoglycoside modifying enzymes often occur with mutations, many subclasses of the enzymes are produced, making more aminoglycosides become the substrates of the modifying enzymes and increasing the antimicrobial resistance [8].

Although aminoglycoside modifying enzymes are the most common resistance mechanism, due to the specificity of substrates, they cannot mediate high-level resistance to multiple aminoglycosides [9]. However, another mechanism of bacterial resistance to aminoglycosides, modification of drug target, leads to high-level resistance against pan-aminoglycoside, with minimal inhibitory concentration (MIC) > 256 µg/mL. There are two ways to modify the drug target: post-transcriptional methylation of 16S rRNA to block aminoglycosides binding to the target [7]; gene point mutation (nucleotide substitution), for example, Mycobacterium tuberculosis rpsL gene encodes S12 protein to mediate streptomycin resistance [10].

3. Plasmid-Mediated 16S rRNA Methylase Resistance Gene and Its Transfer Mechanism

Acquired 16S rRNA methylase is the most clinically significant aminoglycoside resistance mechanism. The concrete resistance mechanism is that with the catalysis of 16S-RMTase, adding a CH$_3$ group provided by S-adenosine methionine (SAM) to specific residues at the A site of 16S rRNA, the binding ability of methylated 16S rRNA to aminoglycosides is significantly reduced, resulting in extensive and high-level resistance to various aminoglycosides [4]. The post-transcriptional modification of 16S rRNA is intrinsic to Actinomycetes (e.g., Streptomyces and Micromonospora) species that produce aminoglycosides to protect themselves from the damage of endogenous aminoglycosides [11,12].

Since the first acquired 16S-RMTase gene was identified in 2003, new genotypes and subtypes have emerged continuously, mediating high-level resistance to a variety of aminoglycosides. So far, a total of eleven acquired 16S-RMTases have been identified and reported, which include ArmA, NpmA, NpmB, and RmtA through RmtH [4,12]. In order to figure out the evolutionary relationships of 16S-RMTases encoding genes and their subtypes, a phylogenetic tree is reconstructed and shown in Figure 1. About the enzymatic function of 16S-RMTases, different types of methyltransferases have different action sites of 16S rRNA: ArmA, RmtA through RmtH methylate N7-G1405 of 16S rRNA and confer high-level resistance to 4,6-disubstituted 2-DOS; NpmA and NpmB methylate N1-A1408 of 16S rRNA and are resistant to 4,5-disubstituted 2-DOS, 4,6-disubstituted 2-DOS, and monosubstituted DOS but only susceptible to streptomycin [1,12,13]. Although the action site is kind of different, the whole types of methyltransferases are able to mediate high-level resistance to pan-aminoglycosides.
Except for the high-level antimicrobial resistance, the 16S-RMTase encoding genes found so far are mostly located within transferable plasmid and/or associated with mobile genetic elements such as transposons, integrons, and insertion sequence [14]. Furthermore, with the support of plasmid and mobile genetic elements, 16S-RMTase encoding genes are often associated with other resistance genes, leading multi-drug resistance even pan-drug resistance. Because of the high-level antimicrobial resistance and the mobility conferred by plasmids as well as other mobile genetic elements, we need pay more attention to the pan-aminoglycoside resistance caused by 16S-RMTase. Here are detailed descriptions of each 16S-RMTase encoding gene and its transfer mechanism; epidemic strains carrying 16S-RMTase encoding genes and their distribution are shown in Table 1, and the genetic context of the 16S-RMTase encoding genes are shown in Figure 2.
Table 1. The strains with 16S rRNA methylase resistance gene and their distribution.

| Genotype | Action Site | MIC (µg/mL) | Subtype | Epidemic Strains | Year of Isolation and Distribution | References |
|----------|-------------|-------------|---------|------------------|------------------------------------|------------|
| armA     | G1405       |             |         | Klebsiella pneumoniae | 2019-Japan, Brazil, Greece, India  |
|          |             | AMK ≥ 256   |         | Escherichia coli    | 2020-China; 2021-Britain; 2022-China |
|          |             | GEN ≥ 256   |         | Acinetobacter baumannii | 2020-India, French; 2021-Britain  |
|          |             | TOB ≥ 256   |         | Enterobacter cloacae | 2018-China; 2020-Greece, Brazil; 2021-Britain |
|          |             | KAN ≥ 256   |         | Citrobacter freundii | 2020-Myanmar; 2021-Britain        |
|          |             |             |         | Salmonella enterica  | 2021-China                         |
|          |             |             |         | Serratia marcescens  | 2020-Turkey                        |
|          |             |             |         | Enterobacter xianfangensis | 2020-India; 2022-China           |
| rmtA     | G1405       |             |         | Pseudomonas aeruginosa | 2003-Japan; 2009-Korea; 2014-Japan; 2017-China |
|          |             | ABK ≥ 512   |         | K. pneumoniae       | 2011-Switzerland; 2021-China       |
|          |             | AMK ≥ 512   |         | E. coli            | 2019-Iran; 2020-India              |
|          |             | GEN ≥ 512   |         |                    | 2017-China                         |
|          |             | KAN ≥ 512   |         |                    |                                     |
|          |             | TOB ≥ 512   |         |                    |                                     |
| rmtB     | G1405       |             |         | E. coli            | 2019-Japan, China, Korea; 2020-India, China, French; 2021-China, Britain, Greece, Kenya; 2022-Switzerland |
|          |             | AMK > 256   |         | K. pneumoniae      | 2019-China, Japan; 2020-China, Japan; 2021-Britain, Brazil, China; 2022-Switzerland |
|          |             | GEN > 256   |         | S. enterica        | 2020-China; 2021-China; 2022-China |
|          |             | KAN > 256   |         | E. cloacae         | 2019-Iran; 2020-China              |
|          |             | TOB > 256   |         | A. baumanii        | 2020-Brazil                        |
|          | rmtB1       |             |         | C. freundii       | 2021-China                         |
|          |             |             |         | Providencia stuartii | 2021-Britain, Greece             |
|          |             |             |         | Proteus mirabilis  | 2021-Greece, China                 |
|          |             |             |         | Klebsiella variicola | 2021-China                        |
|          | rmtB2       |             |         | Providencia rettgeri | 2021-America                      |
|          | rmtB4       |             |         | P. aeruginosa      | 2019-Myanmar; 2021-Egypt, Britain, India |
### Table 1. Cont.

| Genotype | Action Site | MIC (µg/mL) | Subtype | Epidemic Strains | Year of Isolation and Distribution | References |
|----------|-------------|-------------|---------|-----------------|-----------------------------------|------------|
| **rmtC** | G1405       |             |         |                 |                                   |            |
|          |             | AMK > 256   |         | *P. mirabilis*  | 2006-Japan; 2008-Australia        | [15,35,56–73] |
|          |             | GEN > 256   |         | *K. pneumoniae* | 2013-India, Nepal; 2017-Vietnam   |            |
|          |             | TOB ≥ 512   |         | *E. coli*       | 2019-Iran, Albania; 2020-Turkey   |            |
|          |             | ABK = 1024  |         |                 | 2013-India; 2015-Turkey; 2020-India; 2021-Britain |            |
|          |             |             |         | *E. cloaca*     | 2022-Switzerland                   |            |
|          |             |             |         | *Salmonella stanley* | 2012-China                      |            |
|          |             |             |         | *C. freundii*   | 2014-South Africa; 2019-Saudi Arabia; 2021-Britain |            |
|          |             |             |         | *Morganella morgani* | 2020-Turkey                          |            |
|          |             |             |         | *P. aeruginosa* | 2019-China                          |            |
|          |             |             |         | *S. marcescens* | 2018-Ukraine; 2020-Brazil          |            |
|          |             |             |         | *A. baumanii*   | 2019-China                          |            |
|          |             |             |         | *Klebsiella aerogenes* | 2014-South Africa; 2022-Switzerland |            |
|          |             |             |         | *E. xiangfengensis* | 2022-Switzerland                       |            |
| **rmtD** | G1405       |             |         |                 |                                   |            |
|          |             | AMK > 256   |         | *K. pneumoniae* | 2008-Argentina, Chile, Brazil; 2013-America |            |
|          |             | ABK > 256   |         | *E. coli*       | 2020-Turkey; 2021-Brazil          |            |
|          |             | GEN ≥ 256   |         | *E. cloaca*     | 2014-Argentina                     | [55,61,62,74–83] |
|          |             | TOB ≥ 256   |         |                 |                                   |            |
|          |             |             |         |                 |                                   |            |
|          |             |             |         |                 |                                   |            |
| **rmtE** | G1405       |             |         |                 |                                   |            |
Table 1. Cont.

| Genotype | Action Site | MIC (µg/mL) | Subtype | Epidemic Strains | Year of Isolation and Distribution | References |
|----------|-------------|-------------|---------|-----------------|------------------------------------|------------|
| rmtF     | G1405       | AMK ≥ 256   | rmtF1   | K. pneumoniae   | 2012-French; 2013-India, Nepal, Britain; 2014-America; 2015-India; 2016-Egypt; 2018-Switzerland, Britain, Ireland; 2020-China; 2020-India; 2022-Switzerland 2013-India; 2015-India; 2020-India 2015-India; 2021-Egypt 2013-India; 2015-India 2013-India; 2014-South Africa 2015-India 2015-India | [35,36,56–60,62,89–95] |
|          |             | GEN ≥ 256   |         | P. aeruginosa   |                                    |            |
|          |             | TOB ≥ 256   |         | C. freundii     |                                    |            |
|          |             | APR = 2     |         | E. cloacae      |                                    |            |
|          |             |             |         | Citrobacter koseri |                                |            |
|          |             |             |         | P. mirabilis    |                                    |            |
|          |             | AMK > 1024  | rmtF2   | P. aeruginosa   | 2017-Nepal; 2019-Myanmar; 2022-Britain |            |
|          |             | ABK > 1024  |         |                 |                                    |            |
| rmtG     | G1405       | AMK > 256   |         | K. pneumoniae   | 2013-India; 2016-India; 2017-Switzerland 2015-India; 2016-Brazil; 2017-Switzerland 2015-Brazil | [35,59,80,96–102] |
|          |             | GEN > 256   |         | P. aeruginosa   |                                    |            |
|          |             | TOB > 256   |         | E. coli         |                                    |            |
|          |             | ABK > 256   |         | K. aerogenes    |                                    |            |
|          |             |             |         | Enterobacter hormaechei |                              |            |
| rmtH     | G1405       | GEN > 256   |         | K. pneumoniae   | 2013-Iraq; 2017-Lebanon 2020-India | [103,104] |
|          |             | AMK > 256   |         | E. coli         |                                    |            |
|          |             | TOB > 256   |         |                 |                                    |            |
| npmA     | A1408       | KAN > 256   | npmA1   | E. coli         | 2007-China, Japan 2018-Japan 2018-Japan | [13,31,105,106] |
|          |             | TOB > 256   |         | P. aeruginosa   |                                    |            |
|          |             | NEO > 256   |         | K. pneumoniae   |                                    |            |
|          |             | APR > 256   |         |                 |                                    |            |
| npmB     | A1408       | AMK = 64    | npmB1   | E. coli         | 2021-Britain | [12] |
|          |             | TOB = 128   |         |                 |                                    |            |
|          |             | GEN = 32    | npmB2   |                 |                                    |            |
|          |             | NEO = 128   |         |                 |                                    |            |
|          |             | APR = 256   |         |                 |                                    |            |

GEN, Gentamicin; TOB, Tobramycin; AMK, Amikacin; ABK, Arbekacin; NEO, Neomycin; APR, Apramycin; KAN, Kanamycin. Due to space limitations, armA and rmtB genes only list the distribution of epidemic strains around the world from 2019 to 2022, and there is no strain carrying rmtB3 found from 2019 to 2022.
Figure 2. The sequence of the 16S rRNA methylase resistance gene and its genetic environment. GenBank: rmtA, AB083212.2; rmtB, FJ556899.1; rmtC, AB194779.2; rmtD, DQ914960.2; rmtE, KT428293.1; rmtF, JQ808129.1; rmtG, VLNW01000106.1; rmtH, KC544262.1; armA, AY220558.1; npmA, AB261016.2.
3.1. ArmA

The 16S-RMTase gene armA was first identified on a transferable plasmid of *K. pneumoniae* in French [107]. Subsequently, armA has been widely spread throughout the world, primarily found in *A. baumanii, P. rettgeri*, and *K. pneumoniae*, especially prevalent in *A. baumanii*. What is more, armA often came along with the rmtB gene and led to high-level resistance to aminoglycosides with MIC ≥ 256 µg/mL [108–111]. Research studies showed that armA was often located on transferable plasmids belonging to different Inc types [19], and insertion sequences such as IS26 might be involved in the mobilization of resistant genes around pathogens. In addition, these 16S-RMTases producers also showed resistance to β-lactams and carbapenems through various antimicrobial resistance genetic determinants, such as *blaTEM-1*, *blaCTX-M*, *blaNDM*, and other resistance genes [112,113]. The example of armA and its genetic context is shown in Figure 2.

3.2. RmtB

The 16S-RMTase gene rmtB was first identified in *P. aeruginosa* isolated from Japan in 2003 [9]. Then, rmtA gene was also detected among *P. aeruginosa, E. cloacae*, and *K. pneumoniae*, which were isolated from Korea, China, and Switzerland, mediating high-level resistance to aminoglycosides with MIC ≥ 512 µg/mL [9,29,31,114]. Further research studies showed that the type of plasmids carrying rmtA was usually IncA/C [29]. According to the genetic environment around the rmtA gene, it was speculated that rmtA was located on mercury-resistant transposons Tn5041 and mobile genetic elements, such as κ-λ elements and IS6100, flank the rmtA gene and mediate horizontal transfer and homologous recombination between strains [114]. In Figure 2, you can acquire more details of the rmtA and its genetic context which is shown as an example. Several studies had also confirmed that the rmtA gene was usually associated with *blaCTX-M-15, blaNDM-1, blaSHV, blaTEM-1*, and other resistant genes, which largely limits the treatment of multidrug-resistant bacteria [9,114,115].

3.3. RmtC

The 16S-RMTase gene rmtC was first detected in *S. marcescens* isolated from French in 2004 [116]. rmtB is primarily found in *E. coli* and *K. pneumoniae* all over the world and results in resistance to aminoglycosides with MIC ≥ 512 µg/mL [7,51,54,117]. In China, rmtB was the main prevalent genotype of 16S-RMTase and was often combined with armA. Recently, with the development of molecular diagnostic techniques, several alleles of rmtB have been identified: rmtB2 was found in *K. pneumoniae* and *P. rettgeri* [42,103], rmtB3 and rmtB4 were found in *P. aeruginosa* [92]. Compared with the sequence of rmtB1 (GenBank: NG_048058.1), rmtB2 (GenBank: NG_048059.1) showed 96.6% nucleotide identity (26 nucleotides of difference), rmtB3 (GenBank: NG_051535.1) showed 99.6% nucleotide identity (3 nucleotides of difference), and rmtB4 (GenBank: NG_051536.1) showed 97.0% nucleotide identity (23 nucleotides of difference). Compared with RmtB1, the amino acid sequence of RmtB2 had 6 amino acid substitutions: Ala41Thr, Val124Ile, Val132Ile, Thr166Ile, Ile194Leu, and Thr229Ala; RmtB3 had 1 amino acid substitution: Ala82Val; RmtB4 had 4 amino acid substitutions: Val124Ile, Val132Ile, Thr166Ala, and Ile194Leu. Further studies of its genetic environment show that the rmtB gene is usually located on transposons of transferable plasmids with insertion sequences such as ISCR1, ISCfr1, and IS26, leading to the transfer and transmission of rmtB much easier among different strains [118,119]. A typical example of rmtB and its genetic environment is displayed in Figure 2.

3.4. RmtC

The 16S-RMTase gene rmtC was firstly detected in *P. mirabilis* isolated from Japan in 2004 [63]. Since then, rmtC has been spread widely around the world and distributed in various species, such as *K. pneumoniae, E. coli, P. aeruginosa*, and *A. baumanii* [24,60,69], resulting in high-level resistance to aminoglycosides with MIC ≥ 1024 µg/mL [63]. According to the genetic sequences around the rmtC gene, there was an obvious pattern that ISEcp1 was
located upstream of rmtC and played an important role in the expression of rmtC as well as the transfer among different Gram-negative strains [60,63]. This ISEsp1 element belonged to the IS1380 family which was located at the ends of rmtC and contains a transposase gene (InpA) and provided a promoter activity for expression of the adjacent rmtC. This structure enabled the rmtC gene to be transposed onto another plasmid [120,121]. As you can see, in Figure 2, we show an instance of rmtC and its genetic environment to help you understand the above statement. Recently, RmtC methyltransferase has been reported in China and isolated from S. stanley and K. aerogenes respectively. Further studies showed that the multidrug resistance regions and their genetic environment of the two strains’ plasmid were homologous to some extent, associated with carbapenemase and β-lactamase resistance genes such as blaNDM-1 and blaCMY-4 to mediate multidrug resistance [68,73].

3.5. RmtD

The 16S-RMTase gene rmtD was first identified in P. aeruginosa isolated from Brazil in 2007, mainly distributed in South America (such as Brazil, Chile, Argentina, etc.), commonly found in P. aeruginosa and K. pneumoniae [77–79]. Consistent with the characteristics of 16S-RMTase, the strains carrying rmtD show a high level of resistance to aminoglycosides with MIC ≥ 256 µg/mL, even rmtD3 mediates MIC of aminoglycosides up to 1024 µg/mL [75,81].

What is more, several alleles of rmtD have continually been reported in recent years. rmtD2 was isolated from the plasmid of E. aerogenes and C. freundii in Argentina [79] and displayed 97.3% nucleotide identity (20 nucleotides of difference) and 96.4% amino acid identity (9 residues of difference) with RmtD1 [77,79]. The rmtD3 genes were found in two P. aeruginosa strains from Myanmar and Poland, respectively, and both of them were located on chromosomes [81,82]. Compared with RmtD3, there were 9 amino acid substitutions in RmtD and 4 amino acid substitutions in RmtD2 [81]. Recent studies have found that different gene subtypes have different transfer mechanisms. By the means of IS26-mediated recombinational events, rmtD with other genetic elements form complex transposons and may facilitate the future spread of the gene within Enterobacteriaceae [122]. rmtD2 was located on transposon Tn21, and sequence analysis showed that the antimicrobial resistance region of rmtD1 and rmtD2 is formed through transposition or homologous recombination by ISCR3 and ISCR14 [79]. When it comes to rmtD3 identified so far, it often resided in chromosomal mosaic regions, which comprise integrative and conjugative elements (ICEs) with variable cargo regions, carrying IS- or transposon-associated resistance genes [82]. Therefore, with the help of so many transfer elements, rmtD often occurred together with blaESPM-1, blaKPC-2, blaTEM-1, and blaCTX-M-2 [75,77,79]. We draw the Figure 2 to help you understand the genetic context of rmtD more comprehensively.

3.6. RmtE

The 16S-RMTase gene rmtE was first identified in cattle origin E. coli isolated from America in 2010 [84]. In 2014, a case of human infection by RmtE-producing E. coli was firstly reported in America and mediated resistance to aminoglycosides with MIC ≥ 256 µg/mL [85]. Obviously, the distribution of strains carrying rmtE was relatively simple and mainly exists in E. coli. The rmtE2 was identified in swine-origin E. coli isolated from China, which existed in the IncI1 plasmid. More details about rmtE2 were that a single base mutation of T→C is detected at nucleotide 20 of rmtE, which caused a replacement of Val (6) by Ala in the gene product [74]. rmtE was detected among A. baumanii from the UK. Compared with the sequences of rmtE1 and rmtE2 indicated that rmtE3 had two SNPs: one at nucleotide 20 (T→C, Val 7 Ala) and another at nucleotide 141 (T→A, Asn 47 Lys) [87].

According to the genetic environment of rmtE and its alleles, there were several mobile genetic elements that probably mediated the transfer of rmtE between plasmids or between plasmids and chromosomes. rmtE1 was identified on a blaCMY-2-carrying IncA/C plasmid called pYDC637 of E. coli in 2015. Within this unit, rmtE1 was bound by an ISCR20-like
element and an IS1294-like insertion sequence [123]. Interestingly, in 2017, rmtE1 was identified on the chromosome of *E. coli* with a similar structure to the former. It had shown that the subunit containing rmtE1 and its surrounding insertion sequences were similar to that of pYDC637 [86]. As to the genetic environment of rmtE2, an ISCR20-like transposase was located upstream of rmtE2 and an ISVs1-like transposase was located downstream [74]. As reported, there is an ISVs1-like transposase located downstream of rmtE3 [87]. In comparing the genetic context of rmtE1 and rmtE2, ISCR20-like transposase was located upstream of rmtE1 and rmtE2. However, the transposase genes located downstream of the 16S RMTase genes were distinct. ISVs1-like transposase was located downstream of rmtE2 and rmtE3. A general instance of the genetic environment surrounding rmtE is shown in Figure 2. To sum up, whether insertion sequences or broad-host-range, self-conjugative plasmids all played an important role in the initial mobilization of rmtE and the recombination with other resistance genes, such as *bla*TEM-1, *bla*CMY-2, *bla*TEM-1 [15,86,123].

3.7. RmtF

The 16S-RMTase gene *rmtF* was first identified in *K. pneumoniae* isolated from French in 2011, mediating resistance to aminoglycosides with MIC $\geq 256$ µg/mL [89]. Subsequently, *rmtF* has been spread widely around the world, especially in *K. pneumoniae*, as well as can be found in *P. aeruginosa*, *E. coli*, and *C. freundii* [56,59,60,89]. In 2017, a new *rmtF* variant, rmtF2, was identified in *P. aeruginosa* in Nepal mediating resistance to aminoglycosides with MIC up to 1024 µg/mL [92]. Analysis of its predicted amino acid sequence reveals a substitution (Lys65Glu) compared with the sequence of RmtF [92].

Through whole-genome sequencing and analysis of antimicrobial resistance gene sequences, it was found that ISCR5 was often located on both sides of *rmtF* and its allele rmtF2 whether on plasmids or chromosomes, which used to be called insE as shown Figure 2 [89,92]; In recent years, transposase family genes and insertion sequence elements such as Tn3, Tn1721, IS91, and IS6100 also have been found on both sides of *rmtF* or *rmtF2* [62,95]. *rmtF* is usually located on various conjugative plasmids, which belong to broad-host-range compatibility groups such as IncA/C, IncR, IncFII, and IncFIB [58,90,94,95]. With the help of transferable plasmids and insertion sequences, *rmtF* was often associated with β-lactam and carbapenem resistance genes such as *bla*NDM, *bla*CTX-M, *bla*OXA-232, and *bla*TEM-1, especially in *K. pneumoniae* belongs to several high-risk clones ST231, ST147 [90,93,124,125]. The identification of RmtF coresident in strains harboring ESBLs, acquired AmpC enzymes, the NDM-type carbapenemases, and fluoroquinolone-resistance mechanisms not only leads to the potential for coselection and maintenance of resistance by the use of other antibiotics but also seriously compromises the treatment of life-threatening infections caused by Gram-negative organisms [56].

3.8. RmtG

The 16S-RMTase gene *rmtG* was first identified in *K. pneumoniae* isolated from Brazil in 2011, conferring resistance to aminoglycosides with MIC $\geq 256$ µg/mL [80]. At present, the *rmtG* gene was still mainly prevalent in South America, especially in *K. pneumoniae* isolated from Brazil. It also could be found in *K. aerogenes*, *P. aeruginosa*, and *E. coli* isolated in America, India, Switzerland [3,59,96–98,100,101]. However, no strain carrying *rmtG* has been found in China so far.

Further analyses of the mobile genetic elements around the *rmtG* gene showed that *rmtG* was frequently located on the Tn3 transponon of conjugative plasmids belonging to IncN, IncA/C types [80,96,102,126]. What is more, there was another rule that *rmtG* is part of an operon that includes genes related to rRNA and tRNA modification such as *rsmH*, *tgt*, and *rsmL* [101]. Around the multidrug resistance region, *rmtG* was flanked by ISCR2 and IS911-like elements, which were responsible for the mobilization of the array [101,102]. Furthermore, the association of *rmtG* with ISCR2 in a 2-fold tandem repeat suggested a gene amplification process [101]. An example of *rmtG* and its genetic context is shown in Figure 2. In addition, it was important to emphasize that the RmtG-producing
strains such as *K. pneumoniae* were predominantly clonal complex 258 (CC258), which included sequence types such as ST11, ST258, ST437, and ST340 [35,80,96,97,127]. The coproduction of RmtG, ESBLs of the CTX-M type (e.g., CTX-M-2, CTX-M-15, CTX-M-59) and carbapenemases (e.g., KPC-2) could further limit the treatment options for multidrug-resistant bacteria [35,96,101,127].

3.9. RmtH

The reports about *rmtH* were relatively bare. In 2013, the *rmtH* gene was first identified on a conjugative plasmid isolated from *K. pneumoniae* in Iraq, mediating high-level resistance to various aminoglycosides with MIC ≥ 256 µg/mL [103]. In 2017, a strain of *K. pneumoniae* carrying the *rmtH* gene isolated from Lebanon was reported and a complete sequence analysis was carried out. It was found that *rmtH* and *bla*SHV-12 were both located on the same IncFII plasmid, and integrated on the Tn6329 transposon, with IS26 and ISCR2 insertion sequences on both sides involved in the formation of the multidrug resistance region [103,104]. You can find out the surrounding genetic elements of *rmtH* in Figure 2.

3.10. NpmA

The aminoglycoside-resistance 16S-RMTases were functionally divided into two subfamilies that modify the ribosome at either the N7 position of 16S rRNA nucleotide G1405 (m^7^G1405) or the N1 position of A1408 (m^1^A1408). Although enzymes from both subfamilies were found in aminoglycoside-producing bacteria, the m^7^G1405 methyltransferases were far more clinically prevalent than their m^1^A1408 methyltransferase counterparts [128].

NpmA was clinically isolated from *E. coli* strain ARS3 in Japan in 2007 [13]. Due to the posttranslational methylation of the A site of 16S rRNA at position A1408, NpmA leads to pan-aminoglycoside resistance encompassing both 4,5- and 4,6-disubstituted 2-DOS aminoglycosides with MIC ≥ 256 µg/mL, including neomycin and apramycin [12]. So, apramycin resistance seemed to be a good indicator for the detection of an A1408 16S-RMTase producer [13]. Later, the allele of *npmA* was identified in *C. difficile* and named npmA2. The study suggested that hospital-acquired *C. difficile* might be a reservoir for uncommon antibiotic resistance determinants such as *npmA* [105].

In 2021, NpmB was discovered in the process of screening for NpmA-like enzymes in the NCBI sequence databases, whose sequences were identified in *E. coli* genomes registered from the United Kingdom. NpmB1 and NpmB2 consisted of 217 amino acids, and only one amino acid substitution was identified in their sequences at position 21 (arginine for NpmB1 and cysteine for NpmB2). NpmB1 possesses 40% amino acid identity with NpmA1 and conferred resistance to all clinically relevant aminoglycosides, including 4,5-DOS agents. Phylogenetic analysis of NpmB1 and NpmB2, its single-amino-acid variant, revealed that the encoding gene was likely acquired by *E. coli* from a soil bacterium. The structure of NpmB1 suggested that it required a structural change of the β6/7 linker to bind to 16S rRNA. These findings established NpmB1 and NpmB2 as the second group of acquired pan-aminoglycoside resistance 16S-RMTases [12]. In the end, about the genetic context, an example of *npmA* is shown in Figure 2. However, we cannot find the sequence of *npmB*’s genetic context in the NCBI database, so the figure does not contain the *npmB* gene for the moment.

4. Conclusions

With the wide spread of multidrug-resistant bacteria and pan-drug resistant bacteria, monotherapy such as β-lactams or carbapenem for serious infections has become ineffective and unsuccessful. At this moment, the drug combination therapy containing kinds of antibiotics plays an irreplaceable role in the treatment of infectious diseases. As one of the first identified and used clinically, aminoglycoside antibiotics have a broad antimicrobial spectrum and can inhibit both Gram-negative bacteria and part of Gram-positive bacteria [5]. Aminoglycoside antibiotics regain the focus on the clinic as one of the effective options for the drug combination therapy [129].
However, a variety of resistance mechanisms lead to aminoglycosides resistance in bacteria. Among the mechanisms, the production of 16S-RMTases poses a potential threat. The reason for this statement is that they can confer not only complete resistance to a broad range of aminoglycosides but also high-level resistance that cannot be corrected by upregulating the dosage. In addition, several studies have shown that many subtypes of corresponding genotypes often lead to higher levels of resistance to aminoglycosides [81,92]; for example, \( \text{rmtF2} \) is able to mediate resistance to amikacin and arbekacin with MIC > 1024 \( \mu \text{g/mL} \).

What is more, most of the 16S-RMTases encoding genes are often located on transferable plasmids which have a broad host range. With the development of whole-genome sequencing, it is abundantly clear that almost each 16S-RMTases gene is surrounded by some kinds of mobile genetic elements including transposons, integrons, and insertion sequences. Mobile genetic elements and conjugative plasmids not only promote resistance genes to transfer horizontally among all the members of \( \text{Enterobacteriaceae} \) but also up-regulate the expression of the resistance genes resulting in higher MIC [102,120]. From another point of view, there is no doubt that mobile genetic elements also facilitate 16S-RMTases genes to associate with other resistance genes so that forming multidrug resistance regions. The coproduction of 16S-RMTases with ESBLs, AmpC enzymes, and carbapenemases largely limits the drug combination therapy for life-threatening infections caused by multidrug-resistant pathogens [121].

Up to now, there are 2 methods to screen the strain expressing 16S-RMTases: disk diffusion method shows that there is no inhibition zone around multiple aminoglycosides disk or the diameter of inhibition zone shrinking; microbroth dilution method shows that the high-level MIC of multiple aminoglycosides exceeds 128 \( \mu \text{g/mL} \) [14]. If the above results occur, it can be preliminarily determined that the strain carries 16S-RMTase genes. What is more, because of the difference in methylation site, acquired G1405 16S-RMTases and A1408 16S-RMTases confer resistance to different aminoglycosides [12]. For example, apramycin which belongs to 4,5-disubstituted 2-DOS can be used to screen A1408 16S-RMTase [13]. However, the above methods are still not routinely as well as widely applied to the clinical laboratory to detect the resistance phenotypes, enzyme types even corresponding subtypes of 16S-RMTase gene [121]. In the future, it is important to appeal to the clinician and researchers to place particular emphasis on the current situation of aminoglycosides resistance and explore optimized screening procedures and methods to detect the strains expressing 16S-RMTase as early as possible. Additionally, to control the prevalence and global dissemination of multidrug-resistant bacteria, it is highly recommended to evaluate the molecular epidemiology of aminoglycosides resistance genes and perform in-depth analysis of related mobile genetic elements.

**Author Contributions:** Methodology, W.Y. and F.H.; writing—original draft preparation, W.Y.; writing—review and editing, F.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the National Key Research and Development Program of China (2021YFC2701800, 2021YFC2701803), the National Natural Science Foundation of China (grant no. 82172311, 32141002, and 81861138052), and China Antimicrobial Surveillance Network (Independent Medical Grants from Pfizer, 2018QD100). The funders had no role in study design, data collection, analysis, publishing decisions, or manuscript preparation.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Publicly available datasets were analyzed in this study. This data can be found here: https://www.ncbi.nlm.nih.gov/ (accessed on 17 June 2022).

**Conflicts of Interest:** The authors declare no conflict of interest.
Antibiotics 2022, 11, 906

24. da Paz Pereira, J.N.; das Neves de Andrade, C.A.; da Costa Lima, J.L.; de Lima Neto, R.G.; Ramos de Araujo, P.S.; Vieira Maciel, M.A. Clonal Dissemination of Clinical Isolates of Acinetobacter baumannii Carriers of 16S rRNA Methylase Genes in an Oncological Hospital in Recife, Brazil. Curr. Microbiol. 2020, 77, 32–39. [CrossRef] [PubMed]

25. Longo, L.G.A.; de Sousa, V.S.; Kraychete, G.B.; Justo-da-Silva, L.H.; Rocha, J.A.; Superti, S.V.; Bonelli, R.R.; Martins, I.S.; Moreira, B.M. Colistin resistance emerges in pandrug-resistant Klebsiella pneumoniae epidemic clones in Rio de Janeiro, Brazil. Int. J. Antimicrob Agents 2019, 54, 579–586. [CrossRef]

26. Liao, W.; Wang, L.D.; Li, D.; Du, F.-l.; Long, D.; Liu, Y.; Ng, O.; Zhang, W. High Prevalence of 16s rRNA Methylase Genes among Enterobacteriaceae Isolates from Switzerland. Microbiol. Drug Resist. 2021, 27, 44–52. [CrossRef] [PubMed]

27. Aishwarya, K.V.L.; Geetha, P.V.; Shanthi, M.; Uma, S. Co-occurrence of 16S rRNA methyltransferases along with NDM and OXA 48 like carbapenemases on a single plasmid in Klebsiella pneumoniae. J. Lab. Physicians 2019, 11, 305–311. [CrossRef]

28. Jin, J.S.; Kwon, K.T.; Moon, D.C.; Lee, J.C. Emergence of 16S rRNA methylase rmtA in colistin-only-sensitive Pseudomonas aeruginosa in South Korea. Int. J. Antimicrob Agents 2009, 33, 490–491. [CrossRef]

29. Seftian, F.Y.; Mohammadzadeh-Asl, Y.; Ghotaslou, R. High-Level Resistance to Aminoglycosides due to 16S rRNA Methylation in Enterobacteriaceae Isolates. Microbiol. Drug Resist. 2019, 25, 1261–1265. [CrossRef]

30. Nagasawa, M.; Kaku, M.; Kamachi, K.; Shibayama, K.; Arakawa, Y.; Yamaguchi, K.; Ishii, Y. Loop-mediated isothermal amplification assay for 16S rRNA methylase genes in Gram-negative bacteria. J. Infect. Chemother. 2014, 20, 635–638. [CrossRef]

31. Zhao, Z.; Lan, F.; Liu, M.; Chen, W.; Huang, L.; Lin, Q.; Li, B. Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant. Antimicrob. Resist. Infect. Control 2017, 6, 77. [CrossRef] [PubMed]

32. Liao, W.; Wang, L.D.; Li, D.; Du, F.-I.; Long, D.; Liu, Y.; Ng, O.; Zhang, W. High Prevalence of 16s rRNA Methylase Genes among Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae Isolates in a Chinese Tertiary Hospital. Microbiol. Drug Resist. 2021, 27, 44–52. [CrossRef] [PubMed]

33. Sefidan, F.Y.; Mohammadzadeh-Asl, Y.; Ghotaslou, R. High-Level Resistance to Aminoglycosides due to 16S rRNA Methylation in Enterobacteriaceae Isolates. Microbiol. Drug Resist. 2019, 25, 1261–1265. [CrossRef]

34. Wang, W.; Wang, L.; Tao, J.; Li, G.; Jia, W. Emergence of 16S rRNA Methylase Gene mtrA in colistin-only-sensitive Enterobacteriaceae. Chin. J. Infect. Chemother. 2021, 21, 593–598. [CrossRef]

35. Fournier, C.; Poirel, L.; Despont, S.; Kessler, J.; Nordmann, P. Increasing Trends of Association of 16s rRNA Methylases and Carbapenemases in Enterobacteriaceae Clinical Isolates from Switzerland, 2017–2020. Microorganisms 2022, 10, 615. [CrossRef] [PubMed]

36. El-Far, A.; Schrenzel, J.; Cherkaoui, A.; Bernabeu, S.; Renzi, G.; Nordmann, P. Molecular analysis of NDM-1-producing enterobacterial isolates from Geneva, Switzerland. J. Antimicrob. Chemother. 2011, 66, 1730–1733. [CrossRef]

37. Wang, J.; Wang, Z.-Y.; Wang, Y.; Sun, F.; Li, W.; Wu, H.; Shen, P.-C.; Pan, Z.-M.; Jiao, X. Emergence of 16S rRNA Methylase Gene mtrB in Salmonella Enterica Serovar London and Evolution of RmtB-Producing Plasmid Mediated by IS26. Front. Microbiol. 2019, 10, 64278. [CrossRef] [PubMed]

38. Mc Gann, P.; Geringer, M.R.; Hall, L.R.; Lébreton, F.; Markelz, E.; Kwak, Y.I.; Johnson, S.; Ong, A.C.; Powell, A.; Tekle, T.; et al. Pan-drug resistant contributing to a fatal case of COVID-19. J. Med. Microbiol. 2021, 70, 001406. [CrossRef] [PubMed]

39. Roch, M.; Sierra, R.; Sands, K.; Martins, W.M.B.S.; Schrenzel, J.; Walsh, T.R.; Gales, A.C.; Andrey, D.O. Vertical and horizontal dissemination of an IncC plasmid harbouring rmtB 16S rRNA methylase gene, conferring resistance to plazomicin, among invasive ST258 and ST16 KPC-producing Klebsiella pneumoniae. J. Glob. Antimicrob. Resist. 2021, 24, 183–189. [CrossRef]

40. Naflpiotti, K.; Souli, M.; Adamou, P.; Moraitou, E.; Giannopoulou, P.; Chra, P.; Damala, M.; Vogiatzakis, E.; Trikka-Graphakos, E.; Baka, V.; et al. Characterization of 16S rRNA methylase genes in Enterobacteriales and Pseudomonas aeruginosa in Athens Metropolitan area, 2015–2016. Eur. J. Clin. Microbiol. Infect. Dis. 2021, 40, 111–121. [CrossRef]

41. Roch, M.; Sierra, R.; Sands, K.; Martins, W.M.B.S.; Schrenzel, J.; Walsh, T.R.; Gales, A.C.; Andrey, D.O. Vertical and horizontal dissemination of an IncC plasmid harbouring rmtB 16S rRNA methylase gene, conferring resistance to plazomicin, among invasive ST258 and ST16 KPC-producing Klebsiella pneumoniae. J. Glob. Antimicrob. Resist. 2021, 24, 183–189. [CrossRef]

42. Mc Gann, P.; Geringer, M.R.; Hall, L.R.; Lébreton, F.; Markelz, E.; Kwak, Y.I.; Johnson, S.; Ong, A.C.; Powell, A.; Tekle, T.; et al. Pan-drug resistant contributing to a fatal case of COVID-19. J. Med. Microbiol. 2021, 70, 001406. [CrossRef] [PubMed]

43. Masa, B.; Wang, X.; Lei, C.; Tang, Y.; He, J.; Gao, Y.; Zhang, Y.; Wang, H. Identification of Three Novel PmGRI1 Genomic Resistance Islands and One Multidrug Resistant Hybrid Structure of Tn7-like Transposon and PmGRI1 in Proteus mirabilis. Antibiotics 2021, 10, 1268. [CrossRef] [PubMed]

44. Khan, M.; Willcox, M.D.P.; Rice, S.A.; Sharma, S.; Stapleton, F. Development of antibiotic resistance in the ocular Pseudomonas aeruginosa clone ST308 over twenty years. Exp. Eye Res. 2021, 205, 108504. [CrossRef]

45. Huang, L.; Fu, L.; Hu, X.; Liang, X.; Gong, G.; Xie, C.; Zhang, F.; Wang, Y.; Zhou, Y. Co-occurrence of Klebsiella varicola and Klebsiella pneumoniae Both Carrying bla(KPC) from a Respiratory Intensive Care Unit Patient. Infect. Drug Resist. 2021, 14, 4503–4510. [CrossRef]
46. He, D.-D.; Cui, M.-M.; Zhang, T.-L.; Hu, G.-Z.; Liu, J.-H.; Pan, Y.-S. Characterization of blaCMY-2-carrying IncC and rmtB-carrying Incl1/ST136 plasmids in an avian Escherichia coli ST224 strain. Plasmid 2021, 114, 102555. [CrossRef]
47. Cheng, K.; Fang, L.-X.; Ge, Q.-W.; Wang, D.; He, B.; Lu, J.-Q.; Zhong, Z.-X.; Wang, X.-R.; Yu, Y.; Lian, X.-L.; et al. Emergence of fosA3 and bla(CTX-M-14) in Multidrug-Resistant Citrobacter freundii Isolates from Flowers and the Retail Environment in China. Front. Microbiol. 2021, 12, 586504. [CrossRef]
48. Zhu, X.; Li, P.; Qian, C.; Liu, H.; Lin, H.; Zhang, X.; Li, Q.; Lu, J.; Lin, X.; Xu, T.; et al. Prevalence of Aminoglycoside Resistance Genes and Molecular Characterization of a Novel Gene, aac(3)-Ibg, among Clinical Isolates of the Enterobacter cloacae Complex from a Chinese Teaching Hospital. Antimicrob. Agents Chemother. 2020, 64, e00852-20. [CrossRef]
49. Nishida, S.; Ono, Y. Genomic analysis of a pan-resistant Klebsiella pneumoniae sequence type 11 identified in Japan in 2016. Int. J. Antimicrob. Agents 2020, 55, 105884. [CrossRef]
50. Wu, X.; Han, H.; Chen, C.; Zheng, B. Genomic characterisation of a colistin-resistant Klebsiella pneumoniae ST11 strain co-producing KPC-2, FloR, CTX-M-5, SHV-12, FosA and RmtB causing a lethal infection. J. Glob. Antimicrob. Resist. 2019, 19, 78–80. [CrossRef]
51. Uchida, H.; Tada, T.; Tohya, M.; Sugahara, Y.; Kato, A.; Miyairi, I.; Kirikae, T. Emergence in Japan of an isolate of Klebsiella pneumoniae co-harbouring blaKPC-2 and rmtB. J. Glob. Antimicrob. Resist. 2019, 17, 157–159. [CrossRef] [PubMed]
52. Long, H.; Feng, Y.; Ma, K.; Liu, L.; McNally, A.; Zong, Z. The co-transfer of plasmid-borne colistin-resistant genes mcr-1 and mcr-3.5, the carbenapenem gene bla(NDM-5) and the 16S methylase gene rmtB from Escherichia coli. Sci. Rep. 2019, 9, 696. [CrossRef] [PubMed]
53. Belaynehe, K.M.; Won, H.G.; Yoon, I.J.; Yoo, H.S. Prevalence and molecular characteristics of 16s rRNA methylase gene rmtB in amikacin resistant Escherichia coli isolated from South Korea. Korean J. Vet. Res. 2019, 59, 157–160. [CrossRef]
54. Amin, M.; Mehdipour, G.; Navidifar, T. High distribution of 16S rRNA methylase genes and among strains isolated from an Ahvaz teaching hospital, Iran. Acta Microbiol. Immunol. Hung. 2019, 66, 337–348. [CrossRef] [PubMed]
55. Tada, T.; Hishinuma, T.; Watanabe, S.; Uchida, H.; Tohya, M.; Kuwahara-Arai, K.; Mya, S.; Zan, K.N.; Kirikae, T.; Tin, H.H. Molecular Characterization of Multidrug-Resistant Isolates in Hospitals in Myanmar. Antimicrob. Agents Chemother. 2019, 63, e02397-18. [CrossRef] [PubMed]
56. Hidalgo, L.; Hopkins, K.L.; Gutierrez, B.; Ovejero, C.M.; Shukla, S.; Douthwaite, S.; Prasad, K.N.; Woodford, N.; Gonzalez-Zorn, B. Association of the novel aminoglycoside resistance determinant RmtF with NDM carbapenemase in Enterobacteriaceae isolated in India and the UK. J. Antimicrob. Chemother. 2013, 68, 1543–1550. [CrossRef]
57. Tada, T.; Miyoshi-Akiyama, T.; Dahal, R.K.; Mishra, S.K.; Ohara, H.; Shimada, K.; Kirikae, T.; Pokhrel, B.M. Dissemination of multidrug-resistant Klebsiella pneumoniae clinical isolates with various combinations of carbapenemases (NDM-1 and OXA-72) and 16S rRNA methylases (ArmA, RmtC and RmtF) in Nepal. Int. J. Antimicrob. Agents 2013, 42, 372–374. [CrossRef]
58. Rubin, J.E.; Peirano, G.;Peer, A.K.; Govind, C.N.; Pitout, J.D.D. NDM-1-producing Enterobacteriaceae from South Africa: Moving towards endemicity? Diagn. Microbiol. Infect. Dis. 2014, 79, 378–380. [CrossRef]
59. Filgona, J.; Banerjee, T.; Anupurba, S. Incidence of the novel rmtF and rmtG methyltransferases in carbapenem-resistant Enterobacteriaceae from a hospital in India. J. Infect. Dev. Cities. 2015, 9, 1036–1039. [CrossRef]
60. Rahman, M.; Prasad, K.N.; Pathak, A.; Pati, B.K.; Singh, A.; Ovejero, C.M.; Ahmad, S.; Gonzalez-Zorn, B. RmtC and RmtF 16S rRNA Methyltransferase in NDM-1-Producing Pseudomonas aeruginosa. Emerg. Infect. Dis. 2015, 21, 2059–2062. [CrossRef]
61. Erdem, F.; Abulaila, A.; Aktas, Z.; Oncul, O. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains. Antimicrob. Resist. Infect. Control 2020, 9, 70. [CrossRef] [PubMed]
62. Taylor, E.; Jaunekaite, E.; Sriskandan, S.; Woodford, N.; Hopkins, K.L. Detection and characterisation of 16S rRNA methyltransferase-producing Pseudomonas aeruginosa from the UK between 2003–2015. Int. J. Antimicrob. Agents 2022, 59, 106550. [CrossRef] [PubMed]
63. Wachino, J.-I.; Yamane, K.; Shibayama, K.; Kurokawa, H.; Shibata, N.; Suzuki, S.; Doi, Y.; Kimura, K.; Ike, Y.; Arakawa, Y. Novel plasmid-mediated 16S rRNA methylase, RmtC, found in a proteus mirabilis isolate demonstrating extraordinary high-level resistance against various aminoglycosides. Antimicrob. Agents Chemother. 2006, 50, 178–184. [CrossRef] [PubMed]
64. Zong, Z.; Partridge, S.R.; Iredell, J.R. RmtC 16S rRNA methyltransferase in Australia. Antimicrob. Agents Chemother. 2008, 52, 794–795. [CrossRef] [PubMed]
65. Hopkins, K.L.; Escudero, J.A.; Hidalgo, L.; Gonzalez-Zorn, B. 16S rRNA methyltransferase RmtC in Salmonella enterica serovar Virchow. Emerg. Infect. Dis. 2010, 16, 712–715. [CrossRef]
66. Huang, J.; Wang, M.; Ding, H.; Ye, M.; Hu, F.; Guo, Q.; Xu, X.; Wang, M. New Delhi metallo-β-lactamase-1 in carbapenem-resistant Salmonella strain, China. Emerg. Infect. Dis. 2013, 19, 2049–2051. [CrossRef]
67. Kapmaz, M.; Erdem, F.; Abulaila, A.; Yeniarsas, E.; Oncul, O.; Aktas, Z. First detection of NDM-1 with CTX-M-9, TEM, SHV and rmtC in Escherichia coli ST471 carrying Incl2, A/C and Y plasmids from clinical isolates in Turkey. J. Glob. Antimicrob. Resist. 2016, 7, 152–153. [CrossRef]
68. Huang, J.; Deng, S.; Ren, J.; Tu, J.; Ye, M.; Wang, M. Characterization of a blaNDM-1-harboring plasmid from a Salmonella enterica clinical isolate in China. Mol. Med. Rep. 2016, 11, 1087–1092. [CrossRef]
69. Tada, T.; Tsuchiya, M.; Shimada, K.; Nga, T.T.T.; Thu, L.T.A.; Phu, T.T.; Ohmagari, N.; Kirikae, T. Dissemination of Carbapenem-resistant Klebsiella pneumoniae clinical isolates with various combinations of Carbapenemases (KPC-2, NDM-1, NDM-4, and OXA-48) and 16S rRNA Methylases (RmtB and RmtC) in Vietnam. BMC Infect. Dis. 2017, 17, 467. [CrossRef]
Gamal, D.; Fernández-Martínez, M.; Salem, D.; El-Defrawy, I.; Montes, L.A.; Ocampo-Sosa, A.A.; Martinez-Martínez, L. Carbapenem-resistant *Klebsiella pneumoniae* isolates from Egypt containing blaNDM-1 on IncR plasmids and its association with rmtF. *Int. J. Infect. Dis.* 2016, 43, 17–20. [CrossRef] [PubMed]
92. Tada, T.; Shimada, K.; Satou, K.; Hirano, T.; Pokhrel, B.M.; Sherchand, J.B.; Kirikae, T. *Pseudomonas aeruginosa* Clinical Isolates in Nepal Coproducing Metallo-β-Lactamases and 16S rRNA Methytransferases. *Antimicrob. Agents Chemother.* 2017, 61, e00694-17. [CrossRef] [PubMed]

93. Taylor, E.; Srisrandkan, S.; Woodford, N.; Hopkins, K.L. High prevalence of 16S rRNA methyltransferases among carbapenemase-producing *Enterobacteriaceae* in the UK and Ireland. *Int. J. Antimicrob. Agents* 2018, 52, 278–282. [CrossRef]

94. Shankar, C.; Mutthirulandi Sethuvel, D.P.; Neeravi, A.R.; Venkatesan, M.; Devanga Ragupathi, N.K.; Anandan, S.; Veeraraghavan, B. Identification of plasmids by PCR based replicon typing in bacteremic *Klebsiella pneumoniae*. *Microb. Pathog.* 2020, 148, 104429. [CrossRef]

95. Shi, Q.; Han, R.; Guo, Y.; Zheng, Y.; Yang, Y.; Yin, D.; Zhang, R.; Hu, F. Emergence of ST15 Clinical Isolates Producing Plasmid-Mediated RmtF and OXA-232 in China. *Infect. Drug Resist.* 2020, 13, 3125–3129. [CrossRef]

96. Hu, F.; Munoz-Price, L.S.; DePascale, D.; Rivera, J.I.; Doi, Y. *Klebsiella pneumoniae* sequence type 11 isolate producing RmtG 16S rRNA methyltransferase from a patient in Miami, Florida. *Antimicrob. Agents Chemother.* 2014, 58, 4980–4981. [CrossRef]

97. Passarelli-Araujo, H.; Palmeiro, J.K.; Moharana, K.C.; Pedrosa-Silva, F.; Dalla-Costa, L.M.; Venancio, T.M. Molecular epidemiology of 16S RNA methyltransferase in Brazil: RmtG in *Klebsiella aerogenes* ST93 (CC4). *An. Acad. Bras. Cienc.* 2019, 91, e20180762. [CrossRef]

98. Martins, E.R.; Bueno, M.F.C.; Francisco, G.R.; Casella, T.; de Oliveira Garcia, D.; Lincopan, N. Draft Genome Sequence of a Hospital-Associated Clone of *Klebsiella pneumoniae* ST340/CC258 Coproducing RmtG and KPC-2 Isolated from a Pediatric Patient. *Genome Announce.* 2016, 4, e01130-16. [CrossRef]

99. Marsh, J.W.; Pacey, M.P.; Ezeonwuka, C.; Ohm, S.L.; Snyder, D.; Cooper, V.S.; Harrison, L.H.; Doi, Y.; Mustapha, M.M. Clostridium difficile: A potential source of NpmA in the clinical environment. *Exp. Ther. Med.* 2017, 58, 618–619. [CrossRef]

100. Mancini, S.; Poirel, L.; Cortesy, M.; Greub, G.; Nordmann, P. *Klebsiella pneumoniae* co-producing KPC and RmtG, finally targeting Switzerland. *Diagn. Microbiol. Infect. Dis.* 2018, 90, 151–152. [CrossRef]

101. Poirel, L.; Labarca, J.; Bello, H.; Rioseco, M.L.; Bernabeu, S.; Nordmann, P. Emergence of the 16S rRNA methylase RmtG in an extended-spectrum-β-lactamase-producing and colistin-resistant *Klebsiella pneumoniae* isolate in Chile. *Antimicrob. Agents Chemother.* 2014, 58, 618–619. [CrossRef]

102. Martins, E.R.; Bueno, M.F.C.; Francisco, G.R.; Casella, T.; de Oliveira Garcia, D.; Cerdeira, L.; Fernandes, M.R.; Francisco, G.R.; Nora, S.T.R.; Bueno, M.F.C.; da Silva Filho, L.V.; R.F.; de Oliveira Garcia, D. Identification of aminoglycoside-resistance-conferring gene rmtH associated with mobile element ISCR2. *J. Glob. Antimicrob. Resist.* 2020, 20, 36–40. [CrossRef]

103. O’Hara, J.A.; McGann, P.; Snesrud, E.C.; Clifford, R.J.; Waterman, P.E.; Lesho, E.P.; Doi, Y. Novel 16S rRNA methyltransferase RmtH produced by *Klebsiella pneumoniae* associated with war-related trauma. *Antimicrob. Agents Chemother.* 2013, 57, 2413–2416. [CrossRef]

104. Beyrouthy, R.; Robin, F.; Hamze, M.; Bonnet, R. IncFIIk plasmid harbouring an amplification of 16S RNA methyltransferase-encoding gene rmtH associated with mobile element ISCR2. *J. Antimicrob. Chemother.* 2017, 72, 402–406. [CrossRef]

105. Marsh, J.W.; Pacey, M.P.; Ezemonwuka, C.; Ohm, S.L.; Snyder, D.; Cooper, V.S.; Harrison, L.H.; Doi, Y.; Mustapha, M.M. Clostridioideae difficile: A potential source of NpmA in the clinical environment. *J. Antimicrob. Chemother.* 2019, 74, 521–523. [CrossRef]

106. Ishizaki, Y.; Shibuya, Y.; Hayashi, C.; Inoue, K.; Kirikae, T.; Tada, T.; Miyoshi-Akiyama, T.; Ishigaki, M.; Maitani, Y.; Ishida, Y. Instability of the 16S rRNA methyltransferase-encoding npmA gene: Why have bacterial cells possessing npmA not spread despite their high and broad resistance to aminoglycosides? *J. Antimicrob. Chemother.* 2018, 73, 798–807. [CrossRef]

107. Tada, T.; Miyoshi-Akiyama, T.; Dahal, R.K.; Sah, M.K.; Ohara, H.; Shimada, K.; Kirikae, T.; Pokhrel, B.M. NDM-1 Metallo-β-Lactamase and ArmA 16S rRNA methylase producing Providencia rettgeri clinical isolates in Nepal. *BMC Infect. Dis.* 2014, 14, 56. [CrossRef]

108. Wang, Y.; Shen, M.; Yang, J.; Dai, M.; Chang, Y.; Zhang, C.; Luan, G.; Ling, B.; Jia, X. Prevalence of carbapenemases among high-level aminoglycoside-resistant isolates in a university hospital in China. *Exp. Ther. Med.* 2016, 12, 3642–3652. [CrossRef]

109. Tada, T.; Miyoshi-Akiyama, T.; Shimada, K.; Shimojima, M.; Kirikae, T. Dissemination of 16S rRNA methylase ArmA-producing *Pseudomonas aeruginosa* Clinical Isolates in Nepal Coproducing Metallo-β-Lactamases and 16S rRNA Methytransferases. *Antimicrob. Agents Chemother.* 2017, 61, e00694-17. [CrossRef] [PubMed]

110. Beyrouthy, R.; Robin, F.; Hamze, M.; Bonnet, R. IncFIIk plasmid harbouring an amplification of 16S RNA methyltransferase-encoding gene rmtH associated with mobile element ISCR2. *J. Antimicrob. Chemother.* 2017, 72, 402–406. [CrossRef]

111. Marsh, J.W.; Pacey, M.P.; Ezemonwuka, C.; Ohm, S.L.; Snyder, D.; Cooper, V.S.; Harrison, L.H.; Doi, Y.; Mustapha, M.M. Clostridioideae difficile: A potential source of NpmA in the clinical environment. *J. Antimicrob. Chemother.* 2019, 74, 521–523. [CrossRef]

112. Poirel, L.; Labarca, J.; Bello, H.; Rioseco, M.L.; Bernabeu, S.; Nordmann, P. Emergence of the 16S rRNA methylase RmtG in an extended-spectrum-β-lactamase-producing and colistin-resistant *Klebsiella pneumoniae* isolate in Chile. *Antimicrob. Agents Chemother.* 2014, 58, 618–619. [CrossRef]
115. Yamane, K.; Wachino, J.-i.; Doi, Y.; Kurokawa, H.; Arakawa, Y. Global spread of multiple aminoglycoside resistance genes. *Emerg. Infect. Dis.* 2005, 11, 951–953. [CrossRef]

116. Doi, Y.; Yokoyama, K.; Yamane, K.; Wachino, J.-i.; Shibata, N.; Yagi, T.; Shibayama, K.; Kato, H.; Arakawa, Y. Plasmid-mediated 16S rRNA methylase in Serratia marcescens conferring high-level resistance to aminoglycosides. *Antimicrob. Agents Chemother.* 2004, 48, 491–496. [CrossRef]

117. Doi, Y.; Adams-Haduch, J.M.; Paterson, D.L. *Escherichia coli* isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. *Antimicrob. Agents Chemother.* 2008, 52, 1204–1205. [CrossRef]

118. Yuan, L.; Liu, J.-H.; Du, X.-D.; Zong, Z.-Y.; Chen, M.; Hu, G.-Z.; Pan, Y.-S. Comparative genomics of rmtB-carrying IncI1 ST136 plasmids in avian *Escherichia coli* isolates from chickens in China. *Int. J. Antimicrob. Agents* 2018, 51, 659–662. [CrossRef]

119. Du, X.D.; Wu, C.-M.; Liu, H.-B.; Li, X.-S.; Beier, R.C.; Xiao, F.; Qin, S.; Huang, S.-Y.; Shen, J.-Z. Plasmid-mediated ArmA and RmtB 16S rRNA methylases in *Escherichia coli* isolated from chickens. *J. Antimicrob. Chemother.* 2009, 64, 1328–1330. [CrossRef]

120. Wachino, J.-i.; Yamane, K.; Kimura, K.; Shibata, N.; Suzuki, S.; Ike, Y.; Arakawa, Y. Mode of transposition and expression of 16S rRNA methyltransferase gene rmtC accompanied by ISEcp1. *Antimicrob. Agents Chemother.* 2006, 50, 3212–3215. [CrossRef]

121. Mohanam, L.; Menon, T. Emergence of rmtC and rmtF 16S rRNA Methyltransferase in Clinical Isolates of *Pseudomonas aeruginosa*. *Indian J. Med. Microbiol.* 2017, 35, 282–285. [CrossRef]

122. Doi, Y.; Adams-Haduch, J.M.; Paterson, D.L. Genetic environment of 16S rRNA methylase gene rmtD. *Antimicrob. Agents Chemother.* 2008, 52, 2270–2272. [CrossRef]

123. Lee, C.-S.; Li, J.-J.; Doi, Y. Complete sequence of conjugative IncA/C plasmid encoding CMY-2 β-lactamase and RmtE 16S rRNA methyltransferase. *Antimicrob. Agents Chemother.* 2015, 59, 4360–4361. [CrossRef]

124. Mancini, S.; Poirel, L.; Tritten, M.L.; Lienhard, R.; Bassi, C.; Nordmann, P. Emergence of an MDR *Klebsiella pneumoniae* ST231 producing OXA-232 and RmtF in Switzerland. *J. Antimicrob. Chemother.* 2018, 73, 821–823. [CrossRef]

125. Sherchan, J.B.; Tada, T.; Shrestha, S.; Uchida, H.; Hishinuma, T.; Morioka, S.; Shahi, R.K.; Bhandari, S.; Twi, R.T.; Kirikae, T.; et al. Emergence of clinical isolates of highly carbapenem-resistant *Klebsiella pneumoniae* co-harboring *bla*(NDM-5) and *bla*(OXA-181) or-232 in Nepal. *Int. J. Infect. Dis.* 2020, 92, 247–252. [CrossRef]

126. Ramos, P.I.P.; Picão, R.C.; Almeida, L.G.P.d.; Lima, N.C.B.; Girardello, R.; Vivan, A.C.P.; Xavier, D.E.; Barcellos, F.G.; Pelisson, M.; Vespero, E.C.; et al. Comparative analysis of the complete genome of KPC-2-producing *Klebsiella pneumoniae* Kp13 reveals remarkable genome plasticity and a wide repertoire of virulence and resistance mechanisms. *BMC Genom.* 2014, 15, 54. [CrossRef]

127. Bueno, M.F.C.; Francisco, G.R.; Almeida, L.G.P.d.; Lima, N.C.B.; Girardello, R.; Vivan, A.C.P.; Xavier, D.E.; Barcellos, F.G.; Pelisson, M.; Vespero, E.C.; et al. Comparative analysis of the complete genome of KPC-2-producing *Klebsiella pneumoniae* Kp13 reveals remarkable genome plasticity and a wide repertoire of virulence and resistance mechanisms. *BMC Genom.* 2014, 15, 54. [CrossRef]

128. Nosrati, M.; Dey, D.; Mehrani, A.; Strassler, S.E.; Zelinskaya, N.; Hoffer, E.D.; Stagg, S.M.; Dunham, C.M.; Conn, G.L. Functionally critical residues in the aminoglycoside resistance-associated methyltransferase RmtC play distinct roles in 30S substrate recognition. *J. Biol. Chem.* 2019, 294, 17642–17653. [CrossRef]

129. Turnidge, J. Pharmacodynamics and dosing of aminoglycosides. *Infect. Dis. Clin. N. Am.* 2003, 17, 503–528. [CrossRef]